Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap EventNEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (
NASDAQLIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) Near Top of Volume Charts in Wednesday TradingLixte Biotechnology Holdings, Inc. (
NASDAQLIXT) is one today’s most active stocks by volume. So far today, approximately 22.95M shares of Lixte Biotechnology Holdings, Inc. have been exchanged, as compared to an average 30-day volume of 86,145 shares.
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUPPASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced that the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) has authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company’s lead clinical compound, plus doxorubicin versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas (ASTS).
WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)
WestPark Capital, Inc., a full-services investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment with certain institutional investors for $5.8 million of common stock. The Company issued a total of 2,900,000 shares of common stock, at a purchase price of $2.00 per share.
Sidoti Microcap Virtual ConferenceMay 19 - 20, 2021 Presentation times and weblinks released for over 60 presenting companies NEW YORK, NY / ACCESSWIRE / May 18, 2021 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day spring Microcap Virtual Conference taking place Wednesday and Thursday, May 19 - 20, 2021. The links can also be found at www.sidoticonference.com/events. Group Presentation
